Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Pelican Therapeutics (Narrative) (Details)

v3.10.0.1
Acquisition of Pelican Therapeutics (Narrative) (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2016
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Business Acquisition [Line Items]            
Accrued liabilities   $ 1,530,820   $ 1,530,820   $ 2,276,431
Goodwill   2,189,338   2,189,338   $ 2,189,338
Revenue   1,840,009 $ 470,823 3,735,713 $ 906,313  
Net loss (income)   (3,658,562) (2,300,807) (10,795,708) (8,709,659)  
Grant Revenue [Member]            
Business Acquisition [Line Items]            
Revenue   $ 1,800,000 $ 500,000 $ 3,700,000 $ 900,000  
Pelican Therapeutics, Inc. [Member]            
Business Acquisition [Line Items]            
Percentage of voting interests acquired in acquisition   80.00% 80.00% 80.00% 80.00%  
Issuance of common stock Pelican, shares       133,106    
Percentage of outstanding common shares issued for equity consideration in business acquisition       4.99%    
Cash consideration       $ 500,000    
Accrued liabilities   $ 200,000   200,000    
Fair value of contingent consideration   665,936   665,936    
Goodwill   $ 2,189,338   2,189,338    
In-process R&D       $ 5,900,000    
Percentage of non-controlling interest acquired   20.00%   20.00%    
Revenue       $ 15,200,000    
Net loss (income)       2,200,000    
Contract value       7,600,000    
Pelican Therapeutics, Inc. [Member] | Grant Revenue [Member]            
Business Acquisition [Line Items]            
Revenue $ 15,200,000     3,700,000    
Pelican Therapeutics, Inc. [Member] | Stockholders [Member]            
Business Acquisition [Line Items]            
Cash consideration       $ 300,000